Unadjusted and adjusted hazard ratios for angiotensin converting enzyme inhibitor/angiotensin receptor blocker use and new-onset atrial fibrillation in the entire cohort and each of the coronary artery disease sub-groups
| Analysis . | Unadjusted hazard ratio (95% confidence interval) . | Adjusted hazard ratio (95% confidence interval)a . |
|---|---|---|
| Entire cohort (N= 28 620) | 1.16 (1.11–1.21)* | 0.99 (0.94–1.04) |
| CABG cohort (N= 4963) | 1.16 (1.04–1.30)* | 1.00 (0.88–1.14) |
| PCI cohort (N= 11 596) | 1.13 (1.05–1.21)* | 0.95 (0.87–1.04) |
| MI cohort (N= 12 061) | 1.08 (1.01–1.15)* | 0.95 (0.88, 1.03) |
| Analysis . | Unadjusted hazard ratio (95% confidence interval) . | Adjusted hazard ratio (95% confidence interval)a . |
|---|---|---|
| Entire cohort (N= 28 620) | 1.16 (1.11–1.21)* | 0.99 (0.94–1.04) |
| CABG cohort (N= 4963) | 1.16 (1.04–1.30)* | 1.00 (0.88–1.14) |
| PCI cohort (N= 11 596) | 1.13 (1.05–1.21)* | 0.95 (0.87–1.04) |
| MI cohort (N= 12 061) | 1.08 (1.01–1.15)* | 0.95 (0.88, 1.03) |
aAdjusted for age, gender, race, previous myocardial infarction, previous CABG or PCI, history of congestive heart failure, diabetes mellitus, peripheral vascular disease, stroke, hypertension, chronic kidney disease, pre-hospital medication use (statin, β-blocker, angiotensin converting enzyme inhibitor, or angiotensin II receptor blocker), post-hospital medication use within 30 days of discharge (β-blocker, angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, calcium channel blocker, digoxin), year of index hospitalization, teaching hospital, and length of hospital stay.
*P< 0.05.
Unadjusted and adjusted hazard ratios for angiotensin converting enzyme inhibitor/angiotensin receptor blocker use and new-onset atrial fibrillation in the entire cohort and each of the coronary artery disease sub-groups
| Analysis . | Unadjusted hazard ratio (95% confidence interval) . | Adjusted hazard ratio (95% confidence interval)a . |
|---|---|---|
| Entire cohort (N= 28 620) | 1.16 (1.11–1.21)* | 0.99 (0.94–1.04) |
| CABG cohort (N= 4963) | 1.16 (1.04–1.30)* | 1.00 (0.88–1.14) |
| PCI cohort (N= 11 596) | 1.13 (1.05–1.21)* | 0.95 (0.87–1.04) |
| MI cohort (N= 12 061) | 1.08 (1.01–1.15)* | 0.95 (0.88, 1.03) |
| Analysis . | Unadjusted hazard ratio (95% confidence interval) . | Adjusted hazard ratio (95% confidence interval)a . |
|---|---|---|
| Entire cohort (N= 28 620) | 1.16 (1.11–1.21)* | 0.99 (0.94–1.04) |
| CABG cohort (N= 4963) | 1.16 (1.04–1.30)* | 1.00 (0.88–1.14) |
| PCI cohort (N= 11 596) | 1.13 (1.05–1.21)* | 0.95 (0.87–1.04) |
| MI cohort (N= 12 061) | 1.08 (1.01–1.15)* | 0.95 (0.88, 1.03) |
aAdjusted for age, gender, race, previous myocardial infarction, previous CABG or PCI, history of congestive heart failure, diabetes mellitus, peripheral vascular disease, stroke, hypertension, chronic kidney disease, pre-hospital medication use (statin, β-blocker, angiotensin converting enzyme inhibitor, or angiotensin II receptor blocker), post-hospital medication use within 30 days of discharge (β-blocker, angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, calcium channel blocker, digoxin), year of index hospitalization, teaching hospital, and length of hospital stay.
*P< 0.05.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
